Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus

Hideyuki Tamai,Naoki Shingaki,Yoshiyuki Mori,Kosaku Moribata,Akira Kawashima,Yoshimasa Maeda,Toru Niwa,Hisanobu Deguchi,Izumi Inoue,Takao Maekita,Mikitaka Iguchi,Jun Kato,Masao Ichinose

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus

2016

Hideyuki Tamai
Naoki Shingaki
Yoshiyuki Mori
Kosaku Moribata
Akira Kawashima
Yoshimasa Maeda
Toru Niwa
Hisanobu Deguchi
Izumi Inoue
Takao Maekita
Mikitaka Iguchi
Jun Kato
Masao Ichinose

Background/Aims This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using viral response within 2 weeks.

Keywords:

Hepatitis C virus
Hepacivirus
Sustained viral response
Ribavirin
Pegylated interferon
General surgery
Virology
Genotype
Medicine
low dose
Gastroenterology
Diabetes mellitus
Internal medicine
Recombinant DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations